Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Quantitative imaging of gold nanoparticle distribution in a tumor-bearing mouse using benchtop x-ray fluorescence computed tomography.

Manohar N, Reynoso FJ, Diagaradjane P, Krishnan S, Cho SH.

Sci Rep. 2016 Feb 25;6:22079. doi: 10.1038/srep22079.

2.

Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.

Wang Y, Zhang J, Wu Y, Ding ZY, Luo XM, Liu J, Zhong WN, Deng GH, Xia XY, Deng YT, Wei YQ, Jiang Y.

Sci Rep. 2015 Jun 18;5:11275. doi: 10.1038/srep11275.

3.
4.

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.

Hillman GG, Lonardo F, Hoogstra DJ, Rakowski J, Yunker CK, Joiner MC, Dyson G, Gadgeel S, Singh-Gupta V.

Transl Oncol. 2014 May 23. pii: S1936-5233(14)00037-0. doi: 10.1016/j.tranon.2014.04.002. [Epub ahead of print]

5.

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.

Hoh CK, Burris HA 3rd, Bendell JC, Tarazi J, Rosbrook B, Kim S, Infante JR, Reid TR.

Br J Cancer. 2014 Feb 18;110(4):875-81. doi: 10.1038/bjc.2013.806.

6.

Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.

El-Kenawi AE, El-Remessy AB.

Br J Pharmacol. 2013 Oct;170(4):712-29. doi: 10.1111/bph.12344. Review.

7.

Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model.

Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM, Gu YH.

Oncol Lett. 2013 Jul;6(1):69-74.

8.

Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.

Zhang K, Waxman DJ.

Mol Cancer Ther. 2013 May;12(5):787-98. doi: 10.1158/1535-7163.MCT-12-1240.

10.

Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Manley E Jr, Waxman DJ.

J Pharmacol Exp Ther. 2013 Feb;344(2):368-77. doi: 10.1124/jpet.112.200089.

11.
12.

Antiangiogenesis enhances intratumoral drug retention.

Ma J, Chen CS, Blute T, Waxman DJ.

Cancer Res. 2011 Apr 1;71(7):2675-85. doi: 10.1158/0008-5472.CAN-10-3242.

13.

Recent advances in anti-angiogenic therapy of cancer.

Samant RS, Shevde LA.

Oncotarget. 2011 Mar;2(3):122-34. Review.

14.

Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.

Canu B, Fioravanti A, Orlandi P, Di Desidero T, Alì G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, Bocci G.

Neoplasia. 2011 Mar;13(3):217-29.

15.
16.

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Ma J, Waxman DJ.

Mol Cancer Ther. 2008 Dec;7(12):3670-84. doi: 10.1158/1535-7163.MCT-08-0715. Review.

Supplemental Content

Support Center